NCT04564079Completed
An Observational Study to Evaluate the Clinical Utility of the Oncomine Precision Assay Within the Exactis Network
A Multi-Centre Observational Study to Evaluate the Clinical Utility of Returning Genomic Aberration Results Using the Oncomine Precision Assay in Advanced or Metastatic Non-Small Cell Lung Cancer Within the Exactis Network
Source: ClinicalTrials.gov · Last updated 4 Feb 2025
Brief summary (registry, in English)
A Multi-centre Observational Study to Evaluate the Clinical Utility of Returning Genomic Aberration results Using the Oncomine Precision Assay in Advanced or Metastatic Non-Small Cell Lung Cancer Patients within the Exactis Network
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 100 (actual)
- First submitted
- 28 Aug 2020
- Start date
- 1 Jun 2021
- Primary completion date
- 18 Jul 2023
- Lead sponsor
- Exactis Innovation
- Diseases
- Lung cancer
- NCT number
- NCT04564079
What you commit to
- Study type: Observational
- Participants enrolled: 100
- From 1 Jun 2021 to the primary completion date, 18 Jul 2023
- 6 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients who have a history of another active cancer within the past 2 years from date of consent except cervical cancer in situ, basal cell carcinoma of the skin or another in situ carcinoma that is considered cured by the investigator.
Who the study is looking for
- Patients with NSCLC, which is (i) advanced or metastatic (stage IIIb/IV), (ii) non- squamous histology NSCLC as confirmed by local histopathology (mixed squamous and adenocarcinoma is allowed), and has (iii) radiographically measurable disease with at least one bidimensionally measurable lesion of \> 1 cm by CT scan
- No prior treatment for advanced or metastatic NSCLC, except for palliative radiation therapy to non-lung or non-thorax metastases. Patients who received palliative radiation therapy to metastases located within or approximately to the lung or thorax must be evaluated for eligibility.
- Willing and able to provide adequate blood sample prior to starting treatment.
- Willing to provide primary or metastatic tissue, if available.
- Signed and dated Research Ethics Board (REB)-approved informed consent form for Exactis-01 or PMT.
- Not pregnant or breastfeeding
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (6)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre hospitalier universitaire Dr-Georges-L.-Dumont Coordinator of this site? Confirm its status | Moncton | Canada | Unknown status |
| The Moncton Hospital Coordinator of this site? Confirm its status | Moncton | Canada | Unknown status |
| Jewish General Hospital Coordinator of this site? Confirm its status | Montreal | Canada | Unknown status |
| The Ottawa Hospital Coordinator of this site? Confirm its status | Ottawa | Canada | Unknown status |
| Centre hospitalier universitaire de Sherbrooke (CHUS) Coordinator of this site? Confirm its status | Sherbrooke | Canada | Unknown status |
| Princess Margaret Cancer Centre Coordinator of this site? Confirm its status | Toronto | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.